Drug: Xphozah (tenapanor)

Manufacturer: Ardelyx

Route of Administration: Oral

Site of Care: Outpatient

Approved Indication: reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy

Disease: chronic kidney disease

Therapeutic Area: Nephrology

Enrollment Form Link: xphozah-hcp.com/prescribe

Phone Number: 877-527-3927

Fax Number: 877-594-4906

Product Website: xphozah.com